Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
210
datasets available to search
ShareScore release 0.9.0
Dataset results
210 results for “Ebola”
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
ClinicalTrials.gov study NCT02548078. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
ClinicalTrials.gov study NCT02509494. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
ClinicalTrials.gov study NCT02342171. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Partnership for Research on Ebola VACcinations
ClinicalTrials.gov study NCT02876328. IPD Sharing: Not stated. Countries: 4. Publications: 6.
Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
ClinicalTrials.gov study NCT02485912. IPD Sharing: Not stated. Countries: 1. Publications: 47.
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola
ClinicalTrials.gov study NCT04186000. IPD Sharing: NO. Countries: 1. Publications: 14.
Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
ClinicalTrials.gov study NCT04041570. IPD Sharing: NO. Countries: 1. Publications: 6.
PREVAIL VII: Cataract Surgery in Ebola Survivors
ClinicalTrials.gov study NCT03309020. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
ClinicalTrials.gov study NCT02661464. IPD Sharing: Not stated. Countries: 7. Publications: 1.
STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
ClinicalTrials.gov study NCT02378753. IPD Sharing: Not stated. Countries: 1. Publications: 13.
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
ClinicalTrials.gov study NCT02818582. IPD Sharing: Not stated. Countries: 2. Publications: 4.
Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure
ClinicalTrials.gov study NCT02788227. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
ClinicalTrials.gov study NCT02344407. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
ClinicalTrials.gov study NCT02363322. IPD Sharing: Not stated. Countries: 4. Publications: 4.
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
ClinicalTrials.gov study NCT02598388. IPD Sharing: Not stated. Countries: 6. Publications: 2.
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
ClinicalTrials.gov study NCT02485301. IPD Sharing: Not stated. Countries: 4. Publications: 1.
A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
ClinicalTrials.gov study NCT02416453. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
ClinicalTrials.gov study NCT03719586. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Data from: Avoidable errors in the modeling of outbreaks of emerging pathogens, with special reference to Ebola
As an emergent infectious disease outbreak unfolds, public health response is reliant on information on key epidemiological quantities, such as transmission potential and serial interval. Increasingly, transmission models fit to incidence data are used to estimate these parameters and guide policy. Some widely used modelling practices lead to potentially large errors in parameter estimates and, consequently, errors in model-based forecasts. Even more worryingly, in such situations, confidence in parameter estimates and forecasts can itself be far overestimated, leading to the potential for large errors that mask their own presence. Fortunately, straightforward and computationally inexpensive alternatives exist that avoid these problems. Here, we first use a simulation study to demonstrate potential pitfalls of the standard practice of fitting deterministic models to cumulative incidence data. Next, we demonstrate an alternative based on stochastic models fit to raw data from an early phase of 2014 West Africa Ebola virus disease outbreak. We show not only that bias is thereby reduced, but that uncertainty in estimates and forecasts is better quantified and that, critically, lack of model fit is more readily diagnosed. We conclude with a short list of principles to guide the modelling response to future infectious disease outbreaks.
Data from: Spatial spread of the West Africa Ebola epidemic
Controlling Ebola outbreaks and planning an effective response to future emerging diseases are enhanced by understanding the role of geography in transmission. Here we show how epidemic expansion may be predicted by evaluating the relative probability of alternative epidemic paths. We compared multiple candidate models to characterize the spatial network over which the 2013–2015 West Africa epidemic of Ebola virus spread and estimate the effects of geographical covariates on transmission during peak spread. The best model was a generalized gravity model where the probability of transmission between locations depended on distance, population density and international border closures between Guinea, Liberia and Sierra Leone and neighbouring countries. This model out-performed alternative models based on diffusive spread, the force of infection, mobility estimated from cell phone records and other hypothesized patterns of spread. These findings highlight the importance of integrated geography to epidemic expansion and may contribute to identifying both the most vulnerable unaffected areas and locations of maximum intervention value.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.